Neurotoxins and medicinals for the treatment of Parkinson’s disease. Part 3: Drugs indirectly influencing the dopaminergic system (a review)

Author： Kadieva M. Oganesyan É. Mutsueva S.

Publisher： Springer Publishing Company

ISSN： 0091-150X

Source： Pharmaceutical Chemistry Journal, Vol.39, Iss.11, 2005-11, pp. : 565-573

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neurotoxins and medicinals for the treatment of Parkinson’s disease. Part 2: dopamine receptors and their agonists

By Kadieva M. Oganesyan É. Mutsueva S.

Pharmaceutical Chemistry Journal, Vol. 39, Iss. 10, 2005-10 ,pp. : 520-532

Springer Publishing Company

Access to resources Recommend Favorite

Neurotoxins and Drugs for the Treatment of Parkinson's Disease. Part I: Neurotoxins, Levodopa, and Agents Influencing Dopamine Metabolism (A Review)

By Kadieva M. Oganesyan E. Mutsueva S.

Pharmaceutical Chemistry Journal, Vol. 39, Iss. 9, 2005-09 ,pp. : 453-465

Springer Publishing Company

Access to resources Recommend Favorite

Non-dopaminergic drug treatment of Parkinson’s disease

By Müller T.

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 4, 2001-04 ,pp. : 557-572

Informa Healthcare

Access to resources Recommend Favorite

Dopaminergic substitution in Parkinson’s disease

By Müller Thomas

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 10, 2002-10 ,pp. : 1393-1403

Informa Healthcare

Access to resources Recommend Favorite

Existing dopaminergic therapies for Parkinson’s disease

By Dutta PhD Aloke K Le MD PhD Weidong

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 12, 2006-12 ,pp. : 1613-1625

Informa Healthcare

Access to resources Recommend Favorite